Weight-loss drugs known as GLP-1s are growing in popularity, but experts warn their long-term effects and behavioral impacts are not fully understood
One Wellhub client reported spending $25 million a year on GLP-1s for just 1,000 people (more on that in a minute)
Representatives of the sponsor (Novo Nordisk A/S) were involved in the study design
The effectiveness in terms of absorption is generally similar for well-formulated products of either type
These preclinical models allow scientists to investigate key GLP-1 therapeutic pathways, including insulin secretion, glucagon production, gastric emptying, and satiety
28 Oral administration does not appear to diminish the glucose-lowering or weight-lowering efficacy of semaglutide, 29 with oral semaglutide comparing favorably when studied against the SGLT-2 inhibitor empagliflozin